# Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

> **NCT00597493** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 32 (actual)

## Conditions studied

- Recurrent Glioblastoma Multiforme

## Interventions

- **DRUG:** Sorafenib and Temozolomide

## Key facts

- **NCT ID:** NCT00597493
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-02
- **Final completion:** 2010-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00597493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00597493, "Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00597493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*